The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | MRD as a novel primary endpoint in the AURIGA trial
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses the ongoing phase III AURIGA (NCT03901963) study, evaluating whether the addition of daratumumab to lenalidomide maintenance therapy increases the rate of conversion to measurable residual disease (MRD) negativity after 1 year, compared to lenalidomide alone, in patients with newly diagnosed multiple myeloma (MM) who are MRD positive after autologous stem cell transplant. Dr Shah reveals that the use of MRD as an endpoint will allow for earlier assessment of outcomes and evaluation of deeper response than traditional endpoints such as progression-free and overall survival. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
